Literature DB >> 27734469

Idarucizumab for dabigatran overdose in a child.

Susan Shapiro1, Neha Bhatnagar2, Asif Khan3, James Beavis4, David Keeling1.   

Abstract

Entities:  

Keywords:  dabigatran; direct oral anticoagulant; idarucizumab; overdose; reversal

Mesh：

Substances：

Year:  2016        PMID： 27734469     DOI： 10.1111/bjh.14371

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

1.  The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.

Authors:  Pavel Goriacko; Vicken Yaghdjian; Issam Koleilat; Mark Sinnett; Harshal Shukla
Journal:  P T       Date:  2017-11

2.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

Review 3.  Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?

Authors:  Ján Mikler; Matej Samoš; Tomáš Bolek; Ingrid Škorňová; Lucia Stančiaková; Ján Staško; Marián Mokáň
Journal:  Pediatr Cardiol       Date:  2019-07-20       Impact factor: 1.655

Review 4.  Practical Considerations for Use of Direct Oral Anticoagulants in Children.

Authors:  Hilary Whitworth; Leslie Raffini
Journal:  Front Pediatr       Date:  2022-04-01       Impact factor: 3.569

5.  Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.

Authors:  Manuela Albisetti; Arno Schlosser; Martina Brueckmann; Savion Gropper; Stephan Glund; Igor Tartakovsky; Leonardo R Brandão; Paul A Reilly
Journal:  Res Pract Thromb Haemost       Date:  2017-11-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.